IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Position Decreased by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 72,162 shares of the company’s stock after selling 4,273 shares during the quarter. New York State Teachers Retirement System owned about 0.09% of IDEXX Laboratories worth $29,835,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the period. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after acquiring an additional 60 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $444.53 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The business’s fifty day moving average price is $430.95 and its two-hundred day moving average price is $453.11. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The stock has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Finally, Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 in the last quarter. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.